Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research Adds CMS (00867.HK) TP to $17, Keeps Buy Rating
Recommend 2 Positive 5 Negative 1 |
||||
|
||||
|
CMS (00867.HK) launched its Ruxolitinib cream in China, making it the first and only approved targeted drug for treating vitiligo, HSBC Global Research published a research report saying. Ruxolitinib has shown excellent efficacy. Therefore, the broker expected its 2026 sales to reach RMB500 million and double in 2027. HSBC Global Research kept rating at Buy, and added its target price from $16.8 to $17. CMS announced that its subsidiary Dermavon received approval to launch Ruxolitinib phosphate cream in China for treating non-segmental vitiligo for teenagers over 12 years old and adult patients. Ruxolitinib was initially developed by Incyte, with global sales of its oral and cream versions reaching US$2.8 billion and US$500 million each in 2024, representing a YoY growth of 8% and 50%. The drug is the first and only approved targeted treatment for vitiligo in China, targeting approx. 8.2 million patients. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
